VEGFA and systemic sclerosis: In this context, since the bi-specific antibody faricimab, which is simultaneously directed against Ang-2 and VEGF, has recently shown promising results in clinical trials for the treatment of patients with diabetic retinopathy [108], we believe it would be worth investigating its possible efficacy also in SSc.